A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Trial details
- Registry ID
- NCT07677059
- Drugs studied
- KT-621
TrialRedline tracks 3 clinical trials sponsored by Kymera Therapeutics, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma StudyNCT07677059 | KT-621 | Recruiting | 2028-12Estimated |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654 | KT-621 | Recruiting | 2027-12Estimated |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015 | KT-621 | Active not recruiting | 2027-06Estimated |
Names as written in the registry records.
NCT07217015 · Kymera Therapeutics, Inc.
Before: Recruiting. After: Active not recruiting.